Cardiovascular and interventional radiology · 2026
Transarterial Embolization for the Treatment of Symptomatic Hip Osteoarthritis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fleckenstein Florian Nima, Maleitzke Tazio, Oehme Stephan, Donner Stefanie, Auer Timo Alexander, Hildebrandt Alexander, Perka Carsten, Vogel-Claussen Jens, Gebauer Bernhard, Winkler Tobias, Collettini Federico
Аннотация
PURPOSE: To evaluate the safety and clinical effectiveness of transarterial embolization (TAE) using temporary embolic agents in patients with symptomatic hip osteoarthritis (OA) refractory to conservative treatment.
MATERIALS AND METHODS: This single-centre retrospective analysis included patients undergoing TAE between January 2023 and April 2025. Eligibility required ≥ 3 months of clinically and radiographically confirmed hip OA unresponsive to conservative therapy. Embolization was performed using rapidly resorbable gelatin microspheres or imipenem/cilastatin. Outcomes included technical success, adverse events, and patient-reported outcomes (numeric rating scale [NRS] pain; Hip Disability and Osteoarthritis Outcome Score [HOOS]) assessed at baseline and up to 12 months. Clinically meaningful improvement was defined using minimum clinically important difference (MCID) thresholds (≥ 2 points for NRS; ≥ 10 points for HOOS).
RESULTS: Forty-one patients (median age 65 years) underwent TAE with a technical success rate of 97.5% (40/41). The lateral circumflex femoral artery was embolized in all cases, with additional internal iliac branches treated in 27.5% (11/40). No major or moderate adverse events occurred; minor transient skin discoloration was observed in 7.3% (all after imipenem/cilastatin). Median NRS decreased from 7 to 4 at 12 months (p < .001), with significant improvement across all HOOS domains. MCID was achieved in 64.3% for NRS and 85-92% for HOOS. Two patients (4.9%) underwent total hip replacement.
CONCLUSION: TAE using temporary embolic agents was associated with sustained pain reduction and functional improvement at 12 months with a favourable safety profile.
MATERIALS AND METHODS: This single-centre retrospective analysis included patients undergoing TAE between January 2023 and April 2025. Eligibility required ≥ 3 months of clinically and radiographically confirmed hip OA unresponsive to conservative therapy. Embolization was performed using rapidly resorbable gelatin microspheres or imipenem/cilastatin. Outcomes included technical success, adverse events, and patient-reported outcomes (numeric rating scale [NRS] pain; Hip Disability and Osteoarthritis Outcome Score [HOOS]) assessed at baseline and up to 12 months. Clinically meaningful improvement was defined using minimum clinically important difference (MCID) thresholds (≥ 2 points for NRS; ≥ 10 points for HOOS).
RESULTS: Forty-one patients (median age 65 years) underwent TAE with a technical success rate of 97.5% (40/41). The lateral circumflex femoral artery was embolized in all cases, with additional internal iliac branches treated in 27.5% (11/40). No major or moderate adverse events occurred; minor transient skin discoloration was observed in 7.3% (all after imipenem/cilastatin). Median NRS decreased from 7 to 4 at 12 months (p < .001), with significant improvement across all HOOS domains. MCID was achieved in 64.3% for NRS and 85-92% for HOOS. Two patients (4.9%) underwent total hip replacement.
CONCLUSION: TAE using temporary embolic agents was associated with sustained pain reduction and functional improvement at 12 months with a favourable safety profile.